Home / Market News / $VERA

$VERA news and market catalysts

The 9 most recent market catalysts affecting $VERA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

9 catalysts 5 high impact 4 bullish 2 bearish Biotechnology
Nov 13, 2026 Corporate Catalyst Neutral Impact 55
JPMorgan Maintains Buy Rating on Vera Therapeutics
JPMorgan analyst Anupam Rama reaffirmed a 'Buy' rating for Vera Therapeutics (VERA) on November 13, 2026, setting a price target of $75. This analyst action signals continued confi…
Nov 5, 2026 Corporate Catalyst Bullish Impact 85
Vera Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Vera Therapeutics reported its Q3 2026 financial results, highlighting $10.3 million in net product revenue driven by the initial U.S. launch of TRUTAKNA. The company also disclose…
Oct 12, 2026 Corporate Catalyst Neutral Impact 55
Leerink Partners Initiates Coverage On Vera Therapeutics with Market Perform Rating, Announces Price Target of $34
Leerink Partners analyst Will Soghikian has initiated coverage on Vera Therapeutics (VERA) with a 'Market Perform' rating and a $34 price target. This event is significant because …
Oct 2, 2026 Corporate Catalyst Neutral Impact 85
Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy
Vera Therapeutics is presenting the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA in IgA nephropathy (IgAN) at ASN Kidney Week 2026. This is a crucial milestone for th…
Sep 15, 2026 Corporate Catalyst Bullish Impact 95
Vera Therapeutics shares are trading higher after the company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression.
This headline represents a major positive catalyst for Vera Therapeutics. Successful clinical trial results, especially meeting all prespecified endpoints in a Phase 3 trial, signi…
Sep 15, 2026 Corporate Catalyst Bullish Impact 95
Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression
Vera Therapeutics announced highly positive results for its drug TRUTAKNA in the ORIGIN 3 trial for IgA nephropathy, meeting all prespecified efficacy endpoints, including eGFR and…
Sep 8, 2026 Corporate Catalyst Bullish Impact 65
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83
JP Morgan analyst Anupam Rama maintained an 'Overweight' rating on Vera Therapeutics and raised the price target from $76 to $83. This action indicates a positive outlook from a ma…
Aug 11, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Wedbush analyst Laura Chico has reduced the price target for Vera Therapeutics (VERA) from $43 to $34, while keeping a Neutral rating. This action indicates a more conservative out…
Aug 10, 2026 Corporate Catalyst Bearish Impact 92
Vera Therapeutics Q2 EPS $(1.52) Beats $(1.61) Estimate
Vera Therapeutics announced its Q2 earnings, reporting a loss of $(1.52) per share. While this figure represents a 26.67% increase in losses compared to the prior year, it still ma…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.